F. Hoffmann-La Roche AG

Switzerland

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

1 August 2019 - 31 July 2020

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for F. Hoffmann-La Roche AG published between 1 August 2019 - 31 July 2020 which are tracked by the Nature Index.

Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

Count	Share
153	60.62

Outputs by subject (Share)

Subject	Count	Share
Life Sciences	126	42.50
American Journal of Human Genetics	1	0.17
Cancer Research	8	5.60
Cell	4	2.25
Cell Stem Cell	2	0.50
Current Biology	1	0.04
Developmental Cell	1	0.25
Immunity	2	1.01
Journal of Biological Chemistry	2	1.10
Journal of Cell Biology	1	1
Journal of Clinical Investigation	6	0.34
Journal of Experimental Medicine	3	1.15
Journal of Neuroscience	2	2
Molecular Cell	4	1.52
Molecular Psychiatry	4	0.02
Nature	9	4.76
Nature Biotechnology	2	0.07
Nature Cell Biology	1	0.07
Nature Chemical Biology	3	0.34
Nature Communications	19	3.45
Nature Genetics	1	0.48
Nature Immunology	4	0.73
Nature Medicine	7	1.18
Nature Structural & Molecular Biology	2	1.56
Neuron	1	0.03
PLOS Biology	1	0.39
Proceedings of the National Academy of Sciences of the United States of America	12	5.09
Science	6	2.23
Science Advances	3	0.76
Science Translational Medicine	3	2
The EMBO Journal	1	0.05
eLife	10	2.37
Chemistry	33	19.53
Physical Sciences	3	0.75
Earth & Environmental Sciences	1	0.50

Highlight of the month

Changing the channel

A three-dimensional snapshot of a brain protein linked to a neurodevelopmental disorder will provide a template for new drug discovery efforts.

People who inherit mutations in the gene that encodes NALCN — an ion-channel protein that enables the brain to properly control breathing, movement and other basic bodily functions — often suffer from severe neurological disorders and early death.

Now, a team led by scientists from the Roche subsidiary Genentech have used cryo-electron microscopy techniques to map the contours of NALCN. Based on this structural analysis, they showed how mutations in the gene that encodes NALCN alter the shape of a gate that normally controls whether electrical currents can pass through the pore of the ion channel.

Drugs that correct this gating malfunction could thus help reverse the defects caused by the disorder.

Supported content